From a value perspective, I'd say $30 would be high end. rayze got bought for 4.1b US off a small subset of an indication, albeit they were in P3(which they've had to pause due to supply issues).
if cu67 shows significantly superior efficacy with a better safety profile, this may take a large share of the mCRPC market that is moving further up the line in therapy. This is not accounting for their diagnostics or other therapy.
from a realistic perspective, I'm not sure if it'd get to $30, but stranger things have happened(afterpay).
From a value perspective, I'd say $30 would be high end. rayze...
Add CU6 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$7.23 |
Change
0.560(8.40%) |
Mkt cap ! $2.280B | |||
| Open | High | Low | Value | Volume |
| $6.81 | $7.42 | $6.77 | $85.37M | 11.80M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 3000 | $7.21 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $7.26 | 72772 | 1 |
View Market Depth
| Last trade - 16.10pm 30/08/2024 (20 minute delay) ? |
| CU6 (ASX) Chart |